The U.S. Food and Drug Administration ... prescribing information for the Abrysvo (Pfizer) and Arexvy (GlaxoSmithKline) respiratory syncytial virus (RSV) vaccines to include warnings and ...

The prescribing information for Abrysvo ® (respiratory syncytial virus [RSV] vaccine) and Arexvy ® (RSV vaccine, adjuvanted) has been updated to include a new warning regarding the risk of ...

Abrysvo and Arexvy will now be required to come with labeling that includes a warning about a potential increased risk of Guillain-Barré Syndrome. The FDA announced that it has mandated updates to the ...

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

(RTTNews) - The FDA has required the manufacturers of the RSV Vaccines Abrysvo and Arexvy to add a new warning to their labels about the potential risk of Guillain-Barré Syndrome following ...

While issuing its RSV warning mandate on Tuesday, the FDA added that the benefits of vaccination with Abrysvo and Arexvy “continue to outweigh their risks.” During an FDA advisory panel ...

MONDAY, Jan. 13, 2025 (HealthDay News) -- The U.S. Food and Drug Administration ... for the Abrysvo (Pfizer) and Arexvy (GlaxoSmithKline) respiratory syncytial virus (RSV) vaccines to include ...

In the abrysvo or arexvy market, companies aim to expand the vaccine's use across a wider range of age groups by focusing on broader age indications. An example is Pfizer Inc., which received FDA ...

On Tuesday, January 7, the FDA announced it would now be requiring GSK and Pfizer ... of this neurological disorder in patients who had received the Arexvy and Abrysvo vaccine from each firm ...

The petition, first reported by the New York Times, asked the Food and Drug Administration to "revoke Emergency Use Authorizations for existing COVID vaccines and refrain from approving and ...